Our group and others have shown that hyaluronic acid, which signals through CD44 and receptor for hyaluronan mediated motility (RHAMM) receptors, influences GBM migration, proliferation, and therapeutic response.69–71. The gene discussed is CD44; the disease is glioblastoma.